Toca 511 and Toca FC, a two-part cancer-selective immunotherapy, is currently under evaluation in a global Phase 3 trial, called Toca 5, involving patients with first or second recurrence of high-grade glioma, namely glioblastoma or anaplastic astrocytoma, who are undergoing resection.
Tocagen's lead product candidate is comprised of an investigational biologic, Toca 511, and an investigational small molecule, Toca FC. Toca 511 is a retroviral replicating vector that selectively infects cancer cells and delivers a gene for the enzyme, cytosine deaminase. Through this targeted delivery, only infected cancer cells carry the CD gene and produce CD.
Toca FC is an orally administered prodrug, 5-fluorocytosine, which is converted into an anti-cancer drug, 5-fluorouracil, when it encounters CD. 5-FU kills cancer cells and immune-suppressive myeloid cells resulting in anti-cancer immune activation and subsequent tumor killing.
Tocagen is developing product candidates designed to activate a patient's immune system against their cancer. Its lead investigational product candidate, Toca 511 and Toca FC, is being developed initially for the treatment of recurrent high-grade glioma.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886